IP Library Granted Patent US 9,707,331
Granted Patent B2
US 9,707,331 · App. 13/671,549 · Granted Jul 18, 2017

Apparatus for removing chemotherapy compounds from blood

Inventors: Daniel S. Johnston (Trappe, PA); Jacques Chammas (Walpole, MA); William M. Appling (Granville, NY); Samantha J. Barton (Hudson Falls, NY)
Assignee: DELCATH SYSTEMS, INC.
A61M1/34A61M1/3615A61M1/3687B01J20/20B01J20/261B01J20/28011B01J20/28066B01J20/28076B01J20/28078B01J20/3078B01J20/3204B01J20/327B01J20/3293C01B31/083C01B31/084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,331
App. No.
13/671,549
Granted
Jul 18, 2017
Kind
B2
Abstract

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

Claims (41)

1. A filter apparatus for removing small molecule chemotherapy agents from blood comprising:

a housing having an inlet and an outlet; and

an extraction media contained within the housing and comprising carbon cores and a polymer that coats the carbon cores,

wherein the carbon cores each have a pore volume of about 1.68 cc/g to about 2.17 cc/g,

wherein the polymer that coats the carbon cores consists of a material selected from the group comprising cellulose, a methacrylate polymer, or combinations thereof, and

wherein the apparent density of the carbon cores with the polymer that coats the carbon cores is less than about 0.2 g/cc.

2. The filter apparatus according to claim 1 , wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm.

3. The filter apparatus according to claim 1 , wherein the apparent density of the carbon cores with the polymer that coats the carbon cores is about 0.19 g/cc to about 0.2 g/cc.

4. The filter apparatus according to claim 1 , wherein the carbon cores have a median microporous diameter (D 50,micro ) of between about 9.3 Å to about 10.5 Å.

5. The filter apparatus according to claim 1 , wherein the carbon cores have a median mesoporous diameter (D 50,meso ) of between about 30 Å to about 156 Å.

6. The filter apparatus according to claim 1 , wherein microporous pores comprise between about 18% to about 28% of the pore volume of the carbon cores.

7. The filter apparatus according to claim 1 , wherein the carbon cores have a multiple point Brunauer, Emmett and Teller surface area of between about 1825 m 2 /g to about 2058 m 2 /g.

8. The filter apparatus according to claim 1 , wherein the carbon cores have a density functional theory surface area of between about 1483 m 2 /g to about 1778 m 2 /g.

9. The filter apparatus according to claim 1 , wherein the housing includes a hemocompatible filter cartridge.

10. The filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of greater than 98% for removing melphalan hydrochloride from blood using the filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

11. The filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of between about 95% and about 98% for removing melphalan hydrochloride from blood using the filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 500 mL/min.

12. The filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of greater than about 95% for removing melphalan hydrochloride from blood using the filter cartridge in an in vitro system.

13. The filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is doxorubicin and the filter apparatus has an extraction efficiency of greater than about 95% for removing doxorubicin from blood using the filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

14. The filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is topotecan and the filter apparatus has an extraction efficiency of greater than about 89% for removing topotecan from blood using the filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

15. The filter apparatus according to claim 1 , wherein the polymer that coats the carbon cores is a semipermeable polymer.

16. The filter apparatus according to claim 15 , wherein the semipermeable polymer is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof.

17. The filter apparatus according to claim 16 , wherein the semipermeable polymer is polyhydroxyethyl-methacrylate (PHEMA).

18. The filter apparatus according to claim 16 , wherein a weight:weight ratio of carbon to methacrylate is between 52:1 to 25:1.

19. The filter apparatus according to claim 1 , wherein the carbon cores have a multiple point Brunauer, Emmett and Teller surface area of between about 1825 m 2 /g to about 2059 m 2 /g.

20. The filter apparatus according to claim 19 , wherein the carbon cores have a density functional theory surface areabetween about 1483 m 2 /g and about 1778 m 2 /g.

21. The filter apparatus according to claim 19 , wherein the carbon cores have an apparent density between about 0.185 g/cc to about 0.195 g/cc.

22. The filter apparatus according to claim 1 or 19 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of greater than 98% for removing melphalan hydrochloride from blood using a filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

23. The filter apparatus according to claim 1 , wherein the carbon cores are generally spherical.

24. A filter apparatus comprising:

a housing having an inlet and an outlet; and

an extraction media contained within the housing and configured to remove melphalan hydrochloride from blood, the extraction media comprising polymer coated carbon cores,

wherein the polymer coated carbon cores have an apparent density of less than 0.2 g/cc and an extraction efficiency of greater than 98% for removing melphalan hydrochloride from blood.

25. The filter apparatus according to claim 24 , wherein the polymer coated carbon cores have a pore volume of about 1.68 cc/g to about 2.19 cc/g.

26. The filter apparatus according to claim 24 , wherein the polymer coated carbon cores are generally spherical.

27. A filter apparatus for removing melphalan having a concentration less than 15,000 ng/mL from blood, comprising:

one or more filter cartridges comprising an extraction media contained within the one or more filter cartridges and comprising polymer coated carbon cores,

wherein the polymer coated carbon cores have a pore volume of about 1.68 to about 2.19 cc/g and an apparent density of less than about 0.2 g/cc, and

wherein the filter apparatus has an extraction efficiency for melphalan of greater than 98% when blood flows through the filter apparatus at a rate of 500 ml/L or less.

28. The filter apparatus according to claim 27 , wherein the one or more filter cartridges comprises two filter cartridges.

29. The filter apparatus according to claim 28 wherein the two filter cartridges are parallel to each other and flow is split such that fluid passes through the two filter cartridges in parallel.

30. The filter apparatus according to claim 27 , wherein the polymer coated carbon cores are generally spherical.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: DELCATH SYSTEMS, INC.
Reel/Frame 068891/0510 →
SECURITY INTEREST Recorded Sep 20, 2021
From: DELCATH SYSTEMS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057523/0520 →
SECURITY AGREEMENT Recorded Jul 18, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049802/0378 →
SECURITY AGREEMENT Recorded May 24, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049286/0377 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTACHED DOCUMENT PREVIOUSLY RECORDED AT REEL: 049218 FRAME: 0441. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 23, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049283/0694 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 049128 FRAME: 0792. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0633 →
SECURITY AGREEMENT Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0748 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 049127 FRAME: 0954. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENTS. Recorded May 17, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049218/0441 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049128/0792 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049127/0954 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2018
From: HUDSON BAY MASTER FUND LTD.
To: DELCATH SYSTEMS, INC.
Reel/Frame 045624/0355 →
SECURITY INTEREST Recorded Jun 14, 2016
From: DELCATH SYSTEMS, INC.
To: HUDSON BAY MASTER FUND LTD.
Reel/Frame 038911/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: JOHNSTON, DANIEL S.; CHAMMAS, JACQUES; APPLING, WILLIAM M.; BARTON, SAMANTHA J.
To: DELCATH SYSTEMS, INC.
Reel/Frame 030673/0255 →
Continuity (2)
Provisional Application 61556819 · Nov 7, 2011
Related Publication 20130116658A1 · May 9, 2013